COMBINATION OF AR ANTAGONISTS AND TARGETED THORIUM CONJUGATES

摘要: The present invention covers combinations of at least two components, component A and B, comprising being PSMA-TTC, B an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, degrader ARV-110, ARN-terminal domain binder EPI-506, antisense oligonucleotide that reduces expression EZN-4176 AZD-5312, androgen synthesis inhibitor abiraterone, particularly abiraterone seviteronel, galeterone, orteronel ketoconazole, a dual antagonist ODM- 204.. Another aspect the use described herein for preparation medicament treatment prophylaxis disease, particurlarly hyper-proliferative disease.